• HCC: checkpoint inhibitor/VEGF inhibitor combo shows promise

    VEGF has been linked to progression, but can play a role in immunosuppression.

  • Aspirin use is again tied to lower risk for GI cancers

    Meta-analysis of observational studies confirms the association.

  • Statin use may lower risk of hepatocellular carcinoma

    Findings from a meta-analysis of 24 observational studies.

  • Liver cancer: increased incidence driven by older patients with NASH

    Analysis of incidence data from 195 countries and territories.

  • In hepatitis B and C, aspirin use is tied to lower HCC risk

    Mechanistic studies suggest a protective effect, but observational data are flawed.

  • In unresectable HCC, which new targeted therapy is best?

    The newer drugs have been tested against sorafenib, but not each other.

  • HCC: for TACE treatment, twice may be enough

    Evidence-based criteria for stopping TACE are lacking.

  • Survival rates after liver transplantation in the UK
    Survival rates after liver transplantation in the UK

    Mortality rate after liver transplantation has more than halved in the past 20 years.

  • NICE guidance on SIRT for unresectable colorectal liver metastases

    The use of SIRT in patients who can and cannot receive chemotherapy

  • Liver cancer: resection safe and effective in patients ≥80 years
    Liver cancer: resection safe and effective in patients ≥80 years

    Research from St James's University Hospital Trust in Leeds.

  • NAFLD and HCC screening: AGA issues guidelines

    Use noninvasive markers to help decide on screening.

  • HCC: which patients benefit from postoperative TACE?

    Postembolization hypoxia has the potential to lead to negative outcomes in some patients.

  • ASCO-GI 2020 – Unresectable HCC: atezolizumab plus bevacizumab tops sorafenib in patient-reported outcomes

    Quality of life analysis of the IMbrave150 trial.

  • ASCO-GI 2020 – Blood test may detect gastrointestinal cancers

    The test shows high specificity, sensitivity, and predicted tissue of origin.

  • NICE advises against irreversible electroporation for primary liver cancer

    New interventional procedures guidance

  • In biliary tract cancer, adjuvant therapy linked to better survival

    Overall analysis and analysis of randomized trials alone yield similar results.

  • Hepatocellular carcinoma: biomarker may reveal response to transarterial chemoembolization

    Early indicators of response or lack of response to TACE could help prevent aggravation of the patient’s condition.

  • Load more